Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
May 26, 2020
Caladrius Biosciences, Inc. (CLBS) closes RDO (registered direct offering) of 2.084 million shares priced at $2.06
May 19, 2020
bluebird bio (BLUE) proposes 9.09 M share offering priced at $55.00
May 13, 2020
Mesoblast (MESO ASX: MSB) completes US$90 M private placement of 43 M shares
May 11, 2020
bluebird bio (BLUE) to receive $200 M from Bristol Meyers Squibb (BMY)
May 10, 2020
MiMedx (OTC PINK: MDXG) pays back PPP Loan
May 5, 2020
Pluristem Therapeutics (PSTI) initiates a Registered Direct Offering (RDO)
May 1, 2020
RegMed Investors (RMi): April - a roller coaster month ends
April 11, 2020
Regenerative Medicine Earnings Scorecard - Q4 & FY19
April 10, 2020
Sangamo Therapeutics (SGMO) closed its Biogen (BIIB) collaboration agreement
April 7, 2020
Sage Therapeutics (SAGE) Restructuring
March 30, 2020
Athersys (ATHX); HEALIOS K.K., its partner in Japan exercised in full its 4 million warrants to purchase shares at $1.76
March 29, 2020
RegMed Investors’ (RMi): the coming week ...
March 16, 2020
Applied Genetic Technologies Corporation (AGTC) has completed the planned enrollment
February 29, 2020
An introductory homily followed by a short gospel according to Henry
December 6, 2019
Sage Therapeutics' (SAGE) depression (MDD) drug fails in clinical trial missing endpoint, stock price gets its clock cleaned
November 3, 2019
RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector
September 11, 2019
Remember and never forget!
August 5, 2019
Regenerative Medicine Earnings Scorecard - Q2/19 - to date
August 5, 2019
RegMed Investors’ (RMi): Worried about Q2 results, think six (6) market factors…
May 19, 2019
Regenerative Medicine Earnings Scorecard - Q1/19 - to date
March 31, 2019
Regenerative Medicine Earnings Scorecard - Q4/18 and FY18 - to date
March 19, 2019
Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression (severe depression after childbirth) therapy
March 12, 2019
Osiris Therapeutics to be acquired for $660 M or +$19 per share by Smith & Nephew
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2021 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.